Alteration of the lipid and apolipoprotein contents of lipoprotein(a) in haemodialysis patients

被引:4
|
作者
Hugue, V [1 ]
Kandoussi, M [1 ]
Parra, HJ [1 ]
Dracon, M [1 ]
Fruchart, JC [1 ]
Tacquet, A [1 ]
Cachera, C [1 ]
机构
[1] HOP CALMETTE,LAB RECH NEPHROL,LILLE,FRANCE
关键词
apo (a) phenotype; haemodialysis; immunoaffinity; Lp(a) apolipoproteins; Lp(a) lipids;
D O I
10.1093/oxfordjournals.ndt.a027406
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. To examine the possible alteration in Lp(a) composition, protein and lipid contents of Lp (a) were determined in 10 haemodialysis patients (HD) matched with 10 controls (C) for apo(a) phenotypes. Methods. All subjects (HD and C) had Lp(a) concentrations greater than 30 mg/dl (mean +/- SD : 82.3 +/- 41.4 vs 49.3 +/- 22.5 mg/dl), a concentration which has been determined to be associated with an elevated cardiovascular risk. Apo(a)-containing particles were isolated by immunoaffinity chromatography using a monoclonal anti-apo(a) antibody. Results. The molar concentrations of lipid and protein constituents of immunoaffinity isolated Lp(a) were expressed as number of moles per mole of apo(a). Lp(a) from HD patients were significantly richer in apo C111 (P<0.05) and triglycerides (TG) (P<0.05), compared to those of controls. Molar ratios of apo B, apo E, cholesterol and phospholipids per apo(a)-containing particles were in the same range in both groups. Conclusion. Lp(a) from HD patients is characterized by an elevated content in TG and apo C111 in comparison with those of controls. Further studies are needed to evaluate in HD patients the contribution of changes in Lp(a) composition towards the metabolism of these particles.
引用
收藏
页码:825 / 829
页数:5
相关论文
共 50 条
  • [1] LIPID, APOLIPOPROTEIN, AND LIPOPROTEIN(A) LEVELS IN PATIENTS WITH DIFFERENT TYPES OF STROKE
    CHIANG, AN
    HU, HH
    SHAW, GC
    WONG, WJ
    MEDICAL SCIENCE RESEARCH, 1994, 22 (12): : 883 - 885
  • [2] STANDARDIZATION OF LIPID, LIPOPROTEIN, AND APOLIPOPROTEIN MEASUREMENTS
    COOPER, GR
    MYERS, GL
    SMITH, SJ
    SAMPSON, EJ
    CLINICAL CHEMISTRY, 1988, 34 (8B) : B95 - B105
  • [3] RELIABILITY OF LIPID, LIPOPROTEIN, AND APOLIPOPROTEIN MEASUREMENTS
    NAITO, HK
    CLINICAL CHEMISTRY, 1988, 34 (8B) : B84 - B94
  • [4] Apolipoprotein and lipid composition of lipoprotein density classes in dialysis patients.
    Moberly, JB
    Attman, PO
    Samuelsson, O
    KnightGibson, C
    Alaupovic, P
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1025 - A1025
  • [5] Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients
    Eggertsen, G
    Heimburger, O
    Stenvinkel, P
    Berglund, L
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (01) : 141 - 144
  • [6] THE LIPID, LIPOPROTEIN, AND APOLIPOPROTEIN EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
    HODIS, HN
    QUISMORIO, FP
    WICKHAM, E
    BLANKENHORN, DH
    JOURNAL OF RHEUMATOLOGY, 1993, 20 (04) : 661 - 665
  • [7] The effects of serum apolipoprotein E genetic variants and concentration on serum lipid parameters in haemodialysis patients
    Wang, Kai
    Wang, Pei
    Qiao, Yingjin
    Lu, Xiaoqing
    Wang, Xin
    Liu, Zhangsuo
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2015, 67 (05) : 696 - 702
  • [8] Ethnic differences in apolipoprotein contents of HDL associated lipoprotein particles
    Ozcurumez, M
    Wollny, M
    Bilgin, Y
    Gediz, A
    Sinterhauf, K
    Kloer, HU
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 89 - 89
  • [9] SERUM-LIPID, LIPOPROTEIN AND APOLIPOPROTEIN IN DIABETIC NEPHROPATHY
    HWANG, Y
    AHN, JH
    LEE, TW
    IHM, CG
    KIM, MJ
    KIDNEY INTERNATIONAL, 1992, 41 (05) : 1449 - 1449
  • [10] Apolipoprotein E genotype and lipid and lipoprotein levels in dementia
    Wehr, H
    Parnowski, T
    Puzynski, S
    Bednarska-Makaruk, M
    Bisko, M
    Kotapka-Minc, S
    Rodo, M
    Wolkowska, M
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2000, 11 (02) : 70 - 73